SCHEDULE 13G/A: FMR LLC and Abigail P. Johnson Disclose 8.0% Stake in Taysha Gene Therapies Inc.

FMR LLC and Abigail P. Johnson have filed an amended Schedule 13G, reporting a beneficial ownership of 8.0% in Taysha Gene Therapies Inc. as of December 31, 2024.

Summary

• FMR LLC and Abigail P. Johnson collectively beneficially own 16,365,663.87 shares of Taysha Gene Therapies Inc. common stock.
• This ownership represents 8.0% of the total outstanding common stock of Taysha Gene Therapies Inc.
• FMR LLC holds sole voting power over 16,361,024.00 shares and sole dispositive power over 16,365,663.87 shares.
• Abigail P. Johnson, as a Director, Chairman, and CEO of FMR LLC, is also reported as a beneficial owner with sole dispositive power over 16,365,663.87 shares.
• The filing is an Amendment No. 8 to a Schedule 13G, indicating a routine update to a previously disclosed significant ownership position.
• The securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.

Sentiment

Score: 5

Explanation: The document is a factual, routine regulatory filing disclosing beneficial ownership, with no positive or negative operational or financial news about the issuer. Therefore, the sentiment is neutral.

Future Outlook

This document does not contain any forward-looking statements or guidance regarding Taysha Gene Therapies Inc.'s future operations or financial performance.

Management Comments

• "By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §§ 240.14a-11."

Industry Context

This filing is a routine disclosure of an institutional investor's significant stake in a publicly traded company, common in the financial industry for transparency regarding large ownership positions. It does not provide specific insights into Taysha Gene Therapies Inc.'s industry trends or competitive landscape.

Stakeholder Impact

• Shareholders: Provides transparency regarding a significant institutional ownership stake, which can be a factor in assessing investor confidence and potential liquidity.

Key Dates

Keywords

Taysha Gene Therapies Inc., FMR LLC, Abigail P. Johnson, Schedule 13G, beneficial ownership, common stock, institutional investor, equity stake